KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Procter & Gamble (PG) EBT (2016 - 2026)

Procter & Gamble has reported EBT over the past 18 years, most recently at $5.0 billion for Q1 2026.

  • Quarterly EBT rose 7.04% to $5.0 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.0 billion through Mar 2026, up 7.42% year-over-year, with the annual reading at $20.2 billion for FY2025, 7.49% up from the prior year.
  • EBT was $5.0 billion for Q1 2026 at Procter & Gamble, down from $5.4 billion in the prior quarter.
  • Over five years, EBT peaked at $6.0 billion in Q3 2025 and troughed at $3.6 billion in Q2 2022.
  • The 5-year median for EBT is $4.7 billion (2025), against an average of $4.8 billion.
  • The largest YoY upside for EBT was 30.0% in 2024 against a maximum downside of 11.41% in 2024.
  • A 5-year view of EBT shows it stood at $4.8 billion in 2022, then fell by 7.01% to $4.5 billion in 2023, then skyrocketed by 30.0% to $5.8 billion in 2024, then decreased by 7.25% to $5.4 billion in 2025, then decreased by 7.97% to $5.0 billion in 2026.
  • Per Business Quant, the three most recent readings for PG's EBT are $5.0 billion (Q1 2026), $5.4 billion (Q4 2025), and $6.0 billion (Q3 2025).